The most up-to-date regulatory policy information related to pharmaceutical compounding can be found on the


August 30, 2019
Changes to USP <797>, addition of <800> having enormous impact on hospital pharmacies

USP <797> defines how sterile compounding must occur within a hospital pharmacy. The primary focus is on ensuring sterility and stability of compounded products prepared for parenteral administration. This goal is achieved by defining a plethora of practices and environmental requirements by…

Read More
February 5, 2018
Resources for Your Practice

Read More
December 14, 2017
Drug repackagers, compounding pharmacies continue to stress workers' comp systems

The number of physician dispensed prescriptions has declined considerably from just a few years ago, but the workers' compensation industry continues to battle an adapting market seeking to maintain high prices by changing drug strength and formulations. Kathy Fisher, assistant director of external…

Read More
November 6, 2017
Pharmacies say FDA is going too far in enforcing drug compounding law

Compounding pharmacies say FDA overstepped its authority when it enacted the Drug Quality and Security Act (DQSA) of 2013 by not allowing office-use compounding, which is when a pharmacist makes a drug without receiving a prescription and sends it to a requesting physician to hold onto for when it…

Read More
October 30, 2017
Endo International units sue FDA over drug compounding policy

Endo International announced two subsidiaries have sued FDA alleging it improperly authorized the bulk compounding of hundreds of drugs, including "essentially a copy" of Endo's blood pressure drug vasopressin (Vasostrict). The lawsuit comes after FDA Commissioner Scott Gottlieb said last month the…

Read More